Roivant Sciences Stock News
$16.21
1.06%
yesterday
Nasdaq,
Oct 13, 10:03 pm CET
Roivant Sciences Stock News
Neutral
Seeking Alpha
●
19 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I cover U.S. biotech at Bernstein.
Neutral
Seeking Alpha
●
19 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.
Neutral
Seeking Alpha
●
21 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference Call Participants Allison Bratzel - Piper Sandler Brian Cheng - JPMorgan Dave Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Louise Chen - Cantor Yatin Suneja - Guggenh...
Neutral
Seeking Alpha
●
26 days ago
Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Res...
Positive
The Motley Fool
●
27 days ago
Shares of Roivant Sciences (ROIV 12.14%) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday.
Positive
Investors Business Daily
●
27 days ago
Shares of Roivant Sciences extended their breakout Wednesday, stoked by promising test results in a difficult-to-treat autoimmune disease.
Positive
Reuters
●
27 days ago
Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical trial.
Neutral
GlobeNewsWire
●
27 days ago
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
